Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Nucleic Acids Research|September 25, 2018
HACER: an atlas of human active enhancers to interpret regulatory variantsJing Wang, Xizhen Dai, Lynne D Berry, et al.
The Laryngoscope|September 29, 2020
Utilization and Influence of Online Support Communities in Idiopathic Subglottic Stenosis PatientsSunil P Verma, Khodayar Goshtasbi, Lynne D Berry, et al.
The Laryngoscope|September 5, 2023
Association between Estrogen Exposure and Idiopathic Subglottic StenosisNainika Nanda, Li-Ching Huang, Sheau-Chiann Chen, et al.
Cancer|July 26, 2017
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation ConsortiumRathi N Pillai, Madhusmita Behera, Lynne D Berry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.
JTO Clinical and Research Reports|January 27, 2025
Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase InhibitorsNathaniel J Myall, Jennifer G Whisenant, Joel W Neal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperienceBadi El Osta, Madhusmita Behera, Sungjin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2015
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceLynette M Sholl, Dara L Aisner, Marileila Varella-Garcia, et al.
The Journal of Clinical Investigation|January 17, 2023
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancerShidan Wang, Ruichen Rong, Donghan M Yang, et al.
Pageof 2